Last reviewed · How we verify
1 ampoule of Hylan GF-20
1 ampoule of Hylan GF-20 is a Small molecule drug developed by University of Sao Paulo General Hospital. It is currently FDA-approved. Also known as: 1 ampole of Synvisc Classic.
Hylan GF-20, marketed by the University of Sao Paulo General Hospital, is a viscosupplement used in the treatment of osteoarthritis, currently holding a position in the competitive landscape. The drug's key strength lies in its key composition patent, which is set to expire in 2028, providing a period of market exclusivity. The primary risk is the potential increase in competition following the patent expiry, which could impact revenue.
At a glance
| Generic name | 1 ampoule of Hylan GF-20 |
|---|---|
| Also known as | 1 ampole of Synvisc Classic |
| Sponsor | University of Sao Paulo General Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 1 ampoule of Hylan GF-20 CI brief — competitive landscape report
- 1 ampoule of Hylan GF-20 updates RSS · CI watch RSS
- University of Sao Paulo General Hospital portfolio CI
Frequently asked questions about 1 ampoule of Hylan GF-20
What is 1 ampoule of Hylan GF-20?
Who makes 1 ampoule of Hylan GF-20?
Is 1 ampoule of Hylan GF-20 also known as anything else?
What development phase is 1 ampoule of Hylan GF-20 in?
Related
- Manufacturer: University of Sao Paulo General Hospital — full pipeline
- Also known as: 1 ampole of Synvisc Classic
- Compare: 1 ampoule of Hylan GF-20 vs similar drugs
- Pricing: 1 ampoule of Hylan GF-20 cost, discount & access